NCT01778244

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Metformin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic-induced dyslipidemia.

Detailed description

The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention.162 patients were randomized to one of two 24-week individual treatments: metformin (1000mg/day)or placebo. Medications were provided in double-blind fashion.The assessments include lipid levels, body weight, body mass index, fasting glucose, fasting insulin and insulin resistance index.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	metformin	1000mg/day for 24 weeks

Timeline

• Start date: 2008-11-01
• Primary completion: 2011-12-01
• Completion: 2012-06-01
• First posted: 2013-01-29
• Last updated: 2013-01-29

Locations

1 site across 1 country: China